Abstract 1761: Inhibition of PI3K/AKT/mTOR signaling by a dual PI3K/mTOR inhibitor (LY3023414) potentiates the antitumor efficacy of the Chk1 inhibitor prexasertib (LY2606368) in models of human high-grade serous ovarian cancer (HGSOC)

2019 ◽  
Author(s):  
Jack Dempsey ◽  
Greg Donoho ◽  
Philip Iversen ◽  
Jennifer Stephens ◽  
Ann McNulty ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Mtor Inhibitor ◽  
Mtor Signaling ◽  
Antitumor Efficacy ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Chk1 Inhibitor

scholarly journals The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

2019 ◽  
Vol 25 (20) ◽  
pp. 6127-6140 ◽  
Author(s):  
Kalindi Parmar ◽  
Bose S. Kochupurakkal ◽  
Jean-Bernard Lazaro ◽  
Zhigang C. Wang ◽  
Sangeetha Palakurthi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Parp Inhibition ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Cancer Models ◽  
Chk1 Inhibitor

scholarly journals Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor–Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer

2020 ◽  
Vol 80 (23) ◽  
pp. 5380-5392
Author(s):  
Tzu-Ting Huang ◽  
Ethan Brill ◽  
Jayakumar R. Nair ◽  
Xiaohu Zhang ◽  
Kelli M. Wilson ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Antitumor Activity ◽  
Replication Stress ◽  
Mtor Pathway ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Chk1 Inhibitor

Phase 1 Combination Study of the CHK1 inhibitor prexasertib, and the PARP inhibitor olaparib, in high-grade serous ovarian cancer and other solid tumors

2021 ◽  
pp. clincanres.1279.2021
Author(s):  
Khanh Do ◽  
Bose S. Kochupurakkal ◽  
Sarah Kelland ◽  
Adrienne de Jonge ◽  
Jennifer Hedglin ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Solid Tumors ◽  
Phase 1 ◽  
Parp Inhibitor ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Combination Study ◽  
Chk1 Inhibitor
Sign in / Sign up

Export Citation Format

Share Document